-
BioPharma Dive – AI / Data3 months agoLilly’s three-pronged obesity drug hits goal in large diabetes trial
Retatrutide, a possible advance on GLP-1 drugs like Zepbound, significantly cut blood sugar and body weight in the study, a sign it might be similarly impactful...
-
Fierce Biotech3 months ago
Embecta to buy auto-injector maker Owen Mumford for $200M to diversify beyond insulin
Embecta has agreed to pay 100 million pounds sterling upfront for the company, or about $134.3 million, plus another 50 million pounds in sales milestones.
-
BioPharma Dive – AI / Data3 months agoPfizer aims for wider use of PARP drug in prostate cancer with new data
While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should justify use in earlier lines...
-
Biotech Industry Intelligence3 months ago
AstraZeneca deepens UK-China ties with cell therapy R&D hub, manufacturing plans
AstraZeneca deepens UK-China ties with cell therapy R&D hub, manufacturing plans
-
Biotech Industry Intelligence3 months ago
Collegium is acquiring Corium’s approved ADHD drug for $650M
Collegium is acquiring Corium's approved ADHD drug for $650M
-
Uncategorized3 months agoMestag raises $40m to advance therapeutic cancer treatment
Mestag Therapeutics has raised $40 million financing to advance its new therapeutic cancer treatment. The closing of the financing round, led by life science investors SV Health Investors...
-
Fierce Biotech3 months ago
Genentech shreds RIPK1 inhibitor from pipeline after early ph. 2 failure
Genentech has elected to stop a phase 2 trial of a RIPK1 inhibitor early and dump the asset after an analysis revealed the candidate was unlikely...
-
Biotech Industry Intelligence3 months ago
Pfizer seeks earlier use of Talzenna in prostate cancer with Phase 3 win
Pfizer seeks earlier use of Talzenna in prostate cancer with Phase 3 win
-
AI & Machine Learning in Biotechnology3 months agoSTAT+: Eli Lilly’s ‘triple-G’ shows potency, raises concerns
Regulators are trying to push drug development into a post-animal testing era. Meanwhile, a Jennifer Doudna-founded company is edging toward successful CAR-T therapy done in vivo, and...
-
AI & Machine Learning in Biotechnology3 months agoSTAT+: A biotech turns to Apple Watch to study its Parkinson’s drug
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your...
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
An obesity drug deep-dive, and peptides move mainstream
